In itional Application No B 00/03265

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/11 C07K14/47 G01N33/68 A61K38/04

C12N15/62

CO7K19/00

C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{C12N} & \mbox{C07K} & \mbox{G01N} & \mbox{A61K} \end{array}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, BIOSIS, EPO-Internal, WPI Data

Category ° Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
O OGIKUBO ET AL.: "Regulation of Zn-alpha2-glycoproein-mediated cell adhesion by kininogens and their derivatives" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 252, no. 1, 1998, pages 257-262, XP002161541 ACADEMIC PRESS INC. ORLANDO, FL., US ISSN: 0006-291X See Figure 3, peptide P-1	1-4,7-9, 14,17

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents:  'A' document defining the general state of the art which is not considered to be of particular relevance  'E' earlier document but published on or after the international filing date  'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  'O' document referring to an oral disclosure, use, exhibition or other means  'P' document published prior to the international filing date but later than the priority date claimed	<ul> <li>'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>'&amp;' document member of the same patent family</li> </ul>
Date of the actual completion of the international search  27 February 2001	Date of mailing of the international search report  14/03/2001
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Masturzo, P

1

In itiona	Application No
P# B	00/03265

		PF 18 00/03265
C.(Continua Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
	Oldfoll of decalificity, minimized expression of the second expression	
X	B GARCIA-BARRENO ET AL.: "Location of the epitope recognized by monoclonal antibody 63G on the primary structure of human respiratory syncytial virus G glycoprotein and the ability of synthetic peptides containing this epitope to induce neutralizing antibodies"  JOURNAL OF GENERAL VIROLOGY., vol. 73, 1992, pages 2625-2630, XP002161542  SOCIETY FOR GENERAL MICROBIOLOGY, READING., GB ISSN: 0022-1317 See Figure 2, peptide G4	1-4,7-9, 14,17
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LAROCCA, DAVID ET AL: "Establishment of epitope-defined monoclonal antibodies with specificity for fibroblast growth factor receptor types 1 and 2" retrieved from STN Database accession no. 128:281597 CA XP002161545 & HYBRIDOMA (1998), 17(1), 21-31, 1998, abstract	1-4,7-9, 14,17
X	WO 96 14416 A (PIERRE FABRE MEDICAMENT) 17 May 1996 (1996-05-17) see Seq. no. 13	1-4,7-9, 14,17
X	WO 97 30074 A (CYTOGEN CORP. & UNIVERSITY OF NORTH CAROLINA) 21 August 1997 (1997-08-21) see page 94, fourth sequence	1-4,7-9, 14,17
X	FR 2 766 192 A (PIERRE FABRE MEDICAMENT) 22 January 1999 (1999-01-22) see page 29, lines 21-23	1-4,7-9, 14,17
P , X	WO 00 35407 A (TEMPLE UNIVERSITY) 22 June 2000 (2000-06-22) claims 10,11	1-4,7-9, 14,17
Ε	WO 00 64945 A (BABRAHAM INSTITUTE) 2 November 2000 (2000-11-02) see Figure 8, last sequence	1-4,7-9, 14,17
Ρ,Χ	WO 00 43494 A (THE SCRIPPS RESEARCH INSTITUTE) 27 July 2000 (2000-07-27) see sequence no. 70	1-4,7-9, 14,17
		}

1

In itional Application No PCTGB 00/03265

Relevant to claim No.  1-49
1-49
1-49
1-49
1-49

1

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 25,30-41

The compounds of claims 25-30 are defined only by the functional feature to be identifiable through the method of claims 24 or 47 and to be able to interact with Smad. This does not permit a complete search to be carried out due to the vagueness of the subject. The above claim have been searched only insofar as defined in the description as real examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Information on patent family members

Int .tional Application No

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9614416	A	17-05-1996	FR	2726471 A	10-05-1996
			ΑU	712468 B	04-11-1999
			AU	4120296 A	31-05-1996
			BR	1100315 A	23-11-1999
			CA	2204619 A	17-05-1996
			EP	0791064 A	27-08-1997
			JP	10509311 T	14-09-1998
			NZ	296564 A	29-06-1999
			US	6149911 A	21-11-2000
			ZA	9509419 A	28-05-1996
WO 9730074	Α	21-08-1997	AU	726263 B	02-11-2000
			AU	2272397 A	02-09-1997
			CA	2246378 A	21-08-1997
			EP	0897392 A	24-02-1999
			JP	2000506522 T	30-05-2000
FR 2766192	A	22-01-1999	AU	8812398 A	10-02-1999
			BR	9810907 A	01-08-2000
			CN	1264425 T	23-08-2000
			EP	1003851 A	31-05-2000
			MO	9903987 A	28-01-1999
WO 0035407	A	22-06-2000	AU	1749400 A	03-07-2000
WO 0064945	A	02-11-2000	AU	4133800 A	10-11-2000
WO 0043494	Α	27-07-2000	AU	2736600 A	07-08-2000